Overview

Open Label Trial to Assess Iressa in Prostate Cancer Patients

Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
0
Participant gender:
All
Summary
A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Gefitinib
Criteria
Inclusion Criteria:

- Prostate cancer diagnosis

- no evidence of metastasis

- Age 18 or older

Exclusion Criteria:

- Prior chemotherapy for recurrent prostate cancer

- Radiotherapy completed within 28 days of starting the study

- Incomplete healing from prior cancer or other major surgery